Safety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma

1

The study evaluated the safety and efficacy of autologous humanized CD19 CAR-T cell therapy in 26 patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
2

Patients had a median follow-up of 20.3 months, with eligibility criteria including adults aged 18-75 with histologically confirmed R/R B-NHL.
3

The primary endpoint focused on safety, assessing cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome.
4

Efficacy endpoints included overall response rate, progression-free survival, and overall survival, evaluated according to the 2014 Lugano classification.
5

The study highlights the importance of humanization of CAR constructs to improve efficacy and reduce adverse effects in CAR-T cell therapy.

Bone Marrow Transplantation

by Yetian Dong, Tingting Yang, Mengyu Zhao, Fengmei Song, Rongrong Chen, Mingming Zhang, Ruimin Hong, Jingjing Feng, Shan Fu, Pingnan Xiao, Huijun Xu, Jiazhen Cui, Simao Huang, Guoqing Wei, Alex H. Chang, He Huang, Yongxian Hu
August 20, 2025

1